Currently, kidney disease severity can be classified by estimated glomerular filtration rate (GFR) and albuminuria, but more accurate information regarding risk for progression to kidney failure is required for clinical decisions about testing, treatment, and referral. A new, international study from the Chronic Kidney Disease (CKD) Prognosis Consortium found that use of blood levels of cystatin C to estimate kidney function—alone or in combination with creatinine—strengthens the association between kidney function and risks of death and end-stage renal disease. This session will discuss better methods for identifying the subset of patients who are at the highest risk of adverse outcomes and how this could be useful for clinicians and other decision makers.

Learning Objectives
At the end of this educational activity, participants should be able to

1. Evaluate whether combining creatinine, cystatin C, and urine albunin-to-creatinine ratio (ACR) would improve identification of risks associated with CKD compared with creatinine alone
2. Describe the patient populations that would most benefit from using cystatin C in GFR-estimating equations
3. Review whether cystatin C has the potential to make estimates of GFR more accurate
4. Discuss the limitations of estimated GFR creatinine alone for risk predication of CKD

Faculty Listing
William M. McClellan, MD
Professor of Medicine and Epidemiology
Rollins School of Public Health
Emory University
Atlanta, Georgia

Disclosures of Relevant Financial Relationships
In accordance with the ACCME Standards for Commercial Support^SM, OptumHealth Education requires all those involved in the development of activity content to disclose their relevant financial relationships. An individual has a relevant financial relationship if such person (or their spouse/partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the activity content over which the individual has control.
OptumHealth Education ensures that the content is independent of commercial bias.

Method of Participation
There are no fees for participating in or receiving credit for this activity.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

Participants will receive a certificate upon successful completion of the activity, which includes the following:

• Completing the entire activity
• Completing the Pre- and Post-Activity Assessments, Activity Evaluation, and Application for Certificate of Credit forms

You must be logged into your account to participate in this activity. Get started by clicking “Begin” and viewing the “CE Info”; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save, or print your certificate of participation. The Area of Practice you indicated in your profile corresponds with your certificate type. A complete listing of all of your activities can be found under “My Account”, “My Activities.”

Method for Calculating CE Credit
CE credit was calculated by the complexity of content.

Provided By
This activity is provided by OptumHealth Education.

Commercial Support
This activity is supported by an educational grant from Onyx Pharmaceuticals.

Hardware/Software Requirements
To view this activity you will need Internet Explorer 7.0+ or Firefox 3.0+ with Windows Media Player 9+, RealPlayer 12+, or Adobe Flash Player 9+. Be sure to disable your pop-up blocking software prior to the beginning of this activity.